Clinical trialRSS3 days ago
A company called Allrock Bio is testing a new oral medication called ROC-101 for pulmonary hypertension (a condition where blood pressure in the lungs becomes dangerously high). This is a Phase 2a trial, which means they're checking if the drug is safe and works well as an add-on treatment. The trial is now enrolling patients across the U.S., Canada, and Europe.
WHY IT MATTERSIf ROC-101 proves effective as an add-on therapy, it could offer pulmonary hypertension patients a new oral option to combine with their existing treatments, potentially improving symptom control.
Clinical trialUNITERAREApr 3
Researchers at the University of Alabama at Birmingham are looking for premature babies to join a study about pulmonary hypertension—a condition where blood pressure in the lungs gets too high. The study will test different oxygen level targets to see which approach helps prevent or reduce lung problems in preterm infants. This trial is now actively recruiting participants and is expected to start in April 2026.
WHY IT MATTERSThis trial directly addresses a common complication in premature infants where improper oxygen management can cause lasting lung damage, making oxygen saturation targeting strategies critical for improving long-term outcomes in this vulnerable population.